# Tolerability and Pharmacokinetics of CSPCHA115 Capsules in Chinese Healthy Volunteers

> **NCT04161547** · PHASE1 · COMPLETED · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 40 (actual)

## Conditions studied

- Asthma; Allergic Rhinitis

## Interventions

- **DRUG:** CSPCHA115 100 mg; Matching placebo 100 mg
- **DRUG:** CSPCHA115 200 mg; Matching placebo 200 mg
- **DRUG:** CSPCHA115 400 mg; Matching placebo 400 mg
- **DRUG:** CSPCHA115 600 mg; Matching placebo 600 mg

## Key facts

- **NCT ID:** NCT04161547
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-12
- **Primary completion:** 2020-06-01
- **Final completion:** 2020-06-01
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2021-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04161547

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04161547, "Tolerability and Pharmacokinetics of CSPCHA115 Capsules in Chinese Healthy Volunteers". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT04161547. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*